# Marty Makary

Type: Person

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/marty-makary
Canonical HTML page: https://getbiobrief.com/entity/marty-makary

## Timeline

- **2026-08-19**: Trump announces Heidi Overton as FDA Commissioner nominee — President Trump names the White House Domestic Policy Council deputy director to lead the FDA, pending Senate confirmation.
- **2026-05**: Marty Makary resigns as FDA Commissioner — The previous FDA head leaves behind unfinished projects on ultraprocessed foods, antidepressants, and COVID-19 shots.
- **2026-03-11**: Initial Inquiry — The Senator's office begins requesting data on DMD drug approval timelines and internal CBER deliberations.
- **2026-03-10**: Investigation Announced — Sen. Ron Johnson announces a formal probe into the FDA's handling of rare disease drug applications.
- **2026-03-10**: Commissioner Meeting — Johnson meets with FDA Commissioner Marty Makary to discuss specific biologic therapy rejections.

## Recent coverage (4 stories)

### Overton FDA Nomination: 4 Biopharma Risks From Drug Pricing to Vaccines
2026-08-20 00:44:07 · Sentiment: Neutral · Impact: 7/10 · Sources: 2

For biotech and pharma executives, Overton's nomination combines Trump's favored-nation drug pricing push with RFK Jr.'s vaccine skepticism and unfinished reviews of antidepressants and COVID shots. The result could compress margins while opening faster approval pathways for innovation. Investors should watch how she navigates evidence standards and political priorities at the FDA.
Full story: https://getbiobrief.com/story/overton-fda-biopharma-drug-pricing-vaccine-risks

### Trump's 3rd-Choice FDA Pick Overton Shifts Pharma's Regulatory Outlook
2026-08-19 18:17:37 · Sentiment: Neutral · Impact: 7/10 · Sources: 2

Biopharma's key regulator is set to change hands as Trump nominates Heidi Overton, architect of drug-pricing negotiations and vaccine-schedule revisions. Developers and investors are assessing what her confirmation means for approval timelines, pricing pressure, and regulatory predictability.
Full story: https://getbiobrief.com/story/heidi-overton-fda-pharma-regulatory-outlook-bio

### GOP Senator Probes FDA Over Rare Disease Drug Rejections
2026-03-10 22:18:47 · Sentiment: Neutral · Impact: 6/10 · Sources: 2

Senator Ron Johnson (R-Wisc.) has launched an investigation into the FDA's regulatory hurdles for rare disease treatments, specifically targeting biologics for Duchenne muscular dystrophy. The probe follows a direct meeting with FDA Commissioner Marty Makary and signals a significant escalation in political pressure on the agency's approval standards.
Full story: https://getbiobrief.com/story/ron-johnson-fda-rare-disease-investigation

### FDA Commissioner Pushes for New Antidepressant Warnings via Controversial Hire
2026-03-04 20:16:14 · Sentiment: Negative · Impact: 7/10 · Sources: 2

FDA Commissioner Marty Makary is reportedly attempting to hire Dr. Tracy Beth Hoeg to lead a new initiative focused on antidepressant safety. The move is tied to a proposed 'bold new warning' for SSRIs and SNRIs, potentially addressing persistent side effects that have long been a point of contention between regulators and the pharmaceutical industry.
Full story: https://getbiobrief.com/story/fda-makary-hoeg-antidepressant-warning-controversy

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.